Journal of the Chinese Medical Association
Volume 73, Issue 3 , Pages 113-128, March 2010

BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications

  • Kam-Tsun Tang

      Affiliations

    • Department of Medical Education and Research, Taipei, Taiwan, R.O.C.
    • Department of National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Chen-Hsen Lee

      Affiliations

    • Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • Department of National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Chen-Hsen Lee, Department of Surgery, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.

Received 1 September 2009; accepted 11 December 2009.

Article Outline

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein kinase (MAPK) pathway are frequently demonstrated in PTC, such as RET/PTC, RAS, and B-type Raf kinase (BRAF) mutations. Over 90% of BRAF mutations are T1799A, resulting in a BRAFV600E mutation. BRAFV600E is present in ∼50% of PTC and also found in aggressive histologic variants and PTC-derived anaplastic thyroid cancer, but is rare in follicular variants, and not found in follicular thyroid cancer. The tumorigenic role of BRAFV600E in the development of PTC was documented in thyroid-targeted BRAFV600E transgenic mice, and rat thyroid cells overexpressed with BRAFV600E suggested that BRAFV600E is an initiator of tumorigenesis and is required for tumor progression in PTC. Most clinical studies have demonstrated an association of BRAFV600E mutation with aggressive clinicopathologic characteristics and high tumor recurrence, although the results are controversial. The association is also observed in patients with papillary thyroid microcarcinomas and low-risk PTC. As a highly specific and unique mutation in PTC, testing for BRAFV600E in fine-needle aspiration specimens has been shown to refine the diagnostic accuracy of PTC in indeterminate cytology. Preoperative BRAFV600E analysis in low-risk patients may provide important value for prognostication, and these patients might benefit from receiving more intensive management and frequent follow-up. BRAF-targeted therapies have been developed to treat various human cancers including advanced thyroid cancers. Preclinical results are encouraging, but the anticancer effects of clinical trials are disappointing. Studies of multi-kinase inhibitors and/or combination with other regimens are underway in the treatment of advanced thyroid cancers. In this article, we review the pathogenesis of PTC, and the clinical implications of BRAFV600E mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers.

Key Words:  BRAF mutation , fine-needle aspiration cytology , papillary thyroid cancer

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, et al, eds. SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER website, 2009. [Date accessed: December 15, 2009]
  2. Hundahl SA , Fleming ID , Fremgen AM , Menck HR . A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 . Cancer . 1998;83:2638–2648
  3. Dohan O , Baloch Z , Banrevi Z , Livolsi V , Carrasco N . Rapid communication: predominant intracellular overexpression of the Na(+)/I(−) symporter (NIS) in a large sampling of thyroid cancer cases . J Clin Endocrinol Metab . 2001;86:2697–2700
  4. Mazzaferri EL , Jhiang SM . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer . Am J Med . 1994;97:418–428
  5. Mazzaferri EL , Kloos RT . Current approaches to primary therapy for papillary and follicular thyroid cancer . J Clin Endocrinol Metab . 2001;86:1447–1463
  6. Parkin DM , Bray F , Ferlay J , Pisani P . Global cancer statistics, 2002 . CA Cancer J Clin . 2005;55:74–108
  7. Gottlieb JA , Hill CS . Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients . N Engl J Med . 1974;290:193–197
  8. Shimaoka K , Schoenfeld DA , DeWys WD , Creech RH , DeConti R . A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma . Cancer . 1985;56:2155–2160
  9. Döbert N , Menzel C , Oeschger S , Grünwald F . Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients . Thyroid . 2004;14:65–70
  10. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer . Thyroid . 2006;16:109–142
  11. Loh KC , Greenspan FS , Gee L , Miller TR , Yeo PP . Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients . J Clin Endocrinol Metab . 1997;82:3553–3562
  12. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al  Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases . J Clin Endocrinol Metab . 1999;84:4043–4049
  13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al  Mutations of the BRAF gene in human cancer . 2002;417:949–954
  14. Garnett MJ , Marais R . Guilty as charged: B-RAF is a human oncogene . Cancer Cell . 2004;6:313–319
  15. Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications . Endoc Rev . 2007;28:742–762
  16. Puxeddu E , Durante C , Avenia N , Filetti S , Russo D . Clinical implications of BRAF mutation in thyroid carcinoma . Trends Endocrinol Metab . 2008;19:138–145
  17. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF . Cell . 2004;116:855–867
  18. Robinson MJ , Cobb MH . Mitogen-activated protein kinase pathways . Curr Opin Cell Biol . 1997;9:180–186
  19. MacCorkle RA , Tan TH . Mitogen-activated protein kinases in cell-cycle control . Cell Biochem Biophys . 2005;43:451–461
  20. Wittinghofer A , Nassar N . How Ras-related proteins talk to their effectors . Trends Biochem Sci . 1996;21:488–491
  21. Hancock JF . Ras proteins: different signals from different locations . Nat Rev Mol Cell Biol . 2003;4:373–384
  22. Weber CK , Slupsky JR , Herrmann C , Schuler M , Rapp UR , Block C . Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes . Oncogene . 2000;19:169–176
  23. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade . Recent Prog Horm Res . 2001;56:127–155
  24. Malumbres M , Barbacid M . RAS oncogenes: the first 30 years . Nat Rev Cancer . 2003;3:459–465
  25. Chong H , Lee J , Guan KL . Positive and negative regulation of Raf kinase activity and function by phosphorylation . EMBO J . 2001;20:3716–3727
  26. Zhang BH , Guan KL . Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 . EMBO J . 2001;19:5429–5439
  27. Kolch W . Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions . Biochem J . 2000;351:289–305
  28. Morrison DK , Cutler RE . The complexity of Raf-1 regulation . Curr Opin Cell Biol . 1997;9:174–179
  29. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation and role in human cancer . Biochim Biophys Acta . 2007;1773:1196–1212
  30. Mason CS , Springer C , Cooper RG , Superti-Furga G , Marshall CJ , Marais R . Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation . EMBO J . 1999;18:2137–2148
  31. Mercer KE , Pritchard CA . Raf proteins and cancer: B-Raf is identified as a mutational target . Biochim Biophys Acta . 2003;1653:25–40
  32. Marais R , Light Y , Paterson HF , Mason CS , Marshall CJ . Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases . J Biol Chem . 1997;272:4378–4383
  33. Peyssonnaux C , Eychène A . The Raf/MEK/ERK pathway: new concepts of activation . Biol Cell . 2001;93:53–62
  34. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention . Leukemia . 2003;17:1263–1293
  35. Hagemann C , Rapp UR . Isotype-specific functions of Raf kinases . Exp Cell Res . 1999;253:34–46
  36. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al  Activated Raf-1 causes growth arrest in human small cell lung cancer cells . J Clin Invest . 1998;101:153–159
  37. Zhu J , Woods D , McMahon M , Bishop JM . Senescence of human fibroblasts induced by oncogenic Raf . Genes Dev . 1998;12:2997–3007
  38. Wellbrock C , Karasarides M , Marais R . The raf proteins take centre stage . Nat Rev Mol Cell Biol . 2004;5:875–885
  39. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors . Oncogene . 1999;18:813–822
  40. Kimura ET , Nikiforova MN , Zhu Z , Knauf JA , Nikiforov YE , Fagin JA . High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS-BRAF signaling pathway in papillary thyroid carcinoma . Cancer Res . 2003;63:1454–1457
  41. Kondo T , Ezzat S , Asa SL . Pathogenetic mechanisms in thyroid follicular-cell neoplasia . Nat Rev . 2006;6:292–306
  42. Ciampi R , Nikiforov YE . RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis . Endocrinology . 2007;148:936–941
  43. Santoro M , Melillo RM , Fusco A . RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture . Eur J Endocrinol . 2006;155:645–653
  44. Knauf JA , Kuroda H , Basu S , Fagin JA . RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase . Oncogene . 2003;22:4406–4412
  45. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, et al  The RET/PTCRAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells . J Clin Invest . 2005;115:1068–1081
  46. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, et al  BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis . Endocrinology . 2006;147:1014–1019
  47. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, et al  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas . Endocrinology . 1996;137:375–378
  48. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, et al  Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice . Oncogene . 1996;12:1821–1826
  49. Powell DJ, Russell J, Nibu K, Li G, Rhee E, Liao M, et al  The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids . Cancer Res . 1998;58:5523–5528
  50. Nikiforov YE , Rowland JM , Bove KE , Monforte-Munoz H , Fagin JA . Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children . Cancer Res . 1997;57:1690–1694
  51. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C, et al. Detection of activated ras oncogenes in human thyroid carcinomas . Oncogene . 1988;2:403–406
  52. Namba H , Rubin SA , Fagin JA . Point mutations of ras oncogenes are an early event in thyroid tumorigenesis . Mol Endocrinol . 1990;4:1474–1479
  53. Zhu Z , Gandhi M , Nikiforova MN , Fischer AH , Nikiforov YE . Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations . Am J Clin Pathol . 2003;120:71–77
  54. Daum G , Eisenmann-Tappe I , Fries HW , Troppmair J , Rapp UR . The ins and outs of Raf kinases . Trends Biochem Sci . 1994;19:474–480
  55. Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas . Hum Pathol . 2007;38:1810–1818
  56. Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhães J, et al  BRAF mutations are associated with some histological types of papillary thyroid carcinoma . J Pathol . 2004;202:247–251
  57. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer . J Clin Invest . 2005;115:94–101
  58. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, et al  Biochemical and molecular characterization of the novel BRAF (V599Ins) mutation detected in a classic papillary thyroid carcinoma . Oncogene . 2006;25:4235–4240
  59. Hou P , Liu D , Xing M . Functional characterization of the T1799–1801del and A1799–1816ins BRAF mutations in papillary thyroid cancer . Cell Cycle . 2007;6:377–379
  60. Oler G , Ebina KN , Michaluart P , Kimura ET , Cerutti J . Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis . Clin Endocrinol (Oxf) . 2005;62:509–511
  61. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, et al  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma . Thyroid . 2007;17:381–388
  62. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al  The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma . Clin Endocrinol (Oxf) . 2005;63:588–593
  63. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma . J Clin Endocrinol Metab . 2007;92:4085–4090
  64. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, et al  The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma . Int J Oncol . 2004;25:1729–1735
  65. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness . Virchows Arch . 2005;446:589–595
  66. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation . Cancer Res . 2005;65:4238–4245
  67. Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, et al  Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling . Cancer Res . 2006;66:6521–6529
  68. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, et al  Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo . Clin Cancer Res . 2006;12:1785–1793
  69. Salvatore G, Falco V, Salerno P, Nappi T, Pepe S, Troncone G, et al  BRAF is a therapeutic target in aggressive thyroid carcinoma . Clin Cancer Res . 2006;12:1623–1629
  70. Liu D , Liu Z , Condouris S , Xing M . BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells . J Clin Endocrinol Metab . 2007;92:2264–2271
  71. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, et al  Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels . Mol Endocrinol . 2003;17:1425–1436
  72. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis . Oncogene . 2005;24:6646–6656
  73. Owens DM , Keyse SM . Differential regulation of MAP kinase signaling by dual specificity protein phosphatases . Oncogene . 2007;26:3203–3213
  74. Kim HJ , Bar-Sagi D . Modulation of signaling by Sprouty: a developing story . Nat Rev Mol Cell Biol . 2004;5:441–450
  75. Traverse S , Gomez N , Paterson H , Marshall C , Cohen P . Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells: comparison of the effects of nerve growth factor and epidermal growth factor . Biochem J . 1992;288:351–355
  76. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, et al  A module of negative feedback regulators defines growth factor signaling . Nat Genet . 2007;39:503–512
  77. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al  Regulation of Raf-1 by direct feedback phosphorylation . Mol Cell . 2005;17:215–224
  78. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway . Proc Natl Acad Sci USA . 2009;106:4519–4524
  79. Mitsutake N , Knauf JA , Mitsutake S , Mesa C , Zhang L , Fagin JA . Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells . Cancer Res . 2005;65:2465–2473
  80. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 . Cancer Res . 2009;69:4885–4893
  81. Paes JE , Ringel MD . Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia . Endocrinol Metab Clin North Am . 2008;37:375–387
  82. Yamashita S , Saenko V . Mechanisms of disease: molecular genetics of childhood thyroid cancers . Nat Clin Pract Endocrinol Metab . 2007;3:422–429
  83. Dal Maso L , Bosetti C , La Vecchia C , Franceschi S . Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors . Cancer Causes Control . 2009;20:75–86
  84. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al  Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies . Radiat Res . 1995;141:259–277
  85. Moysich KB , Menezes RJ , Michalek AM . Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review . Lancet Oncol . 2002;3:269–279
  86. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, et al  Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas . Cancer Lett . 2004;209:1–6
  87. Lee JH , Lee ES , Kim YS , Won NH , Chae YS . BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas . Pathology . 2006;38:201–204
  88. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al  BRAF(V600E) mutation and the biology of papillary thyroid cancer . Endocr Relat Cancer . 2008;15:191–205
  89. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al  Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer . J Clin Endocrinol Metab . 2009;94:1612–1617
  90. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al  Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas . Am J Surg Pathol . 2006;30:216–222
  91. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, et al  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature . Endocr Relat Cancer . 2006;13:455–464
  92. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al  The prevalence and prognostic value of BRAF mutation in thyroid cancer . Ann Surg . 2007;246:466–471
  93. Kim KH , Suh KS , Kang DW , Kang DY . Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis . Pathol Int . 2005;55:540–545
  94. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas . J Clin Endocrinol Metab . 2003;88:5399–5404
  95. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, et al  BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid ≤ 1 cm and their paired lymph node metastases . Cancer . 2007;110:1218–1226
  96. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, et al  Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure . J Pathol . 2005;205:558–564
  97. Xu X , Quiros RM , Gattuso P , Ain KB , Prinz RA . High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines . Cancer Res . 2003;63:4561–4567
  98. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al  The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma . Clin Endocrinol (Oxf) . 2006;65:364–368
  99. Oler G , Cerutti JM . High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes . Cancer . 2009;115:972–980
  100. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study . J Clin Endocrinol Metab . 2008;93:3943–3949
  101. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, et al  Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer . J Clin Endocrinol Metab . 2006;91:3667–3670
  102. Riesco-Eizaguirre G , Gutierrez-Martinez P , Garcia-Cabezas MA , Nistal M , Santisteban P . The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I– targeting to the membrane . Endocr Relat Cancer . 2006;13:257–269
  103. Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al  The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma . J Clin Endocrinol Metab . 2007;92:3511–3516
  104. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, et al  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer . Oncogene . 2007;23:7436–7440
  105. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers . J Clin Endocrinol Metab . 2003;88:4393–4397
  106. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer . J Clin Endocrinol Metab . 2005;90:6373–6379
  107. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, et al  High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes . J Clin Endocrinol Metab . 2005;90:5265–5269
  108. Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma . Clin Endocrinol (Oxf) . 2008;69:683–685
  109. Lee J , Lee ES , Kim YS . Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis . Cancer . 2007;110:38–46
  110. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma . Clin Cancer Res . 2009;15:485–491
  111. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al  BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients . Endocr J . 2009;56:89–97
  112. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status . Int J Cancer . 2007;120:196–200
  113. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism . J Clin Endocrinol Metab . 2007;92:2840–2843
  114. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, et al  No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan . Clin Endocrinol (Oxf) . 2005;63:461–466
  115. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, et al  Targeting BRAFV600E in thyroid carcinoma: therapeutic implications . Mol Cancer Ther . 2007;6:1070–1078
  116. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, et al  Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci . Cancer . 2006;107:1831–1838
  117. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al  BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas . J Clin Endocrinol Metab . 2004;89:2414–2420
  118. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, et al  Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) . Eur J Endocrinol . 2006;154:341–348
  119. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al  BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer . Endocr Relat Cancer . 2008;15:511–520
  120. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al  Molecular characteristics in papillary thyroid cancers (PTCs) with no (131)I uptake . Clin Endocrinol (Oxf) . 2008;68:108–116
  121. Di Cristofaro J , Silvy M , Lanteaume A , Marcy M , Carayon P , De Micco C . Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes . Endocr Relat Cancer . 2006;13:485–495
  122. Liu D , Hu S , Hou P , Jiang D , Condouris S , Xing M . Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant . Clin Cancer Res . 2007;13:1341–1349
  123. Ikuyama S , Niller HH , Shimura H , Akamizu T , Kohn LD . Characterization of the 5′-flanking region of the rat thyrotropin receptor gene . Mol Endocrinol . 1992;6:793–804
  124. Yokomori N , Tawata M , Saito T , Shimura H , Onaya T . Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein . Mol Endocrinol . 1998;12:1241–1249
  125. American Association of Clinical Endocrinologists and Associazione MediciEndocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules . Endocr Pract . 2006;12:63–102
  126. Pacini F , Schlumberger M , Dralle H , Elisei R , Smit JW , Wiersinga W . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium . Eur Endocrinol . 2006;154:787–803
  127. Leenhardt L , Grosclaude P , Chérié-Challine L , Thyroid Cancer Committee  . Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee . Thyroid . 2004;14:1056–1060
  128. Davies L , Welch HG . Increasing incidence of thyroid cancer in the United States, 1973–2002 . JAMA . 2006;295:2164–2167
  129. Burgess JR , Dwyer T , McArdle K , Tucker P , Shugg D . The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978–1998) during a transition from iodine sufficiency to iodine deficiency . J Clin Endocrinol Metab . 2000;85:1513–1517
  130. Chow SM, Law SC, Au SK, Mang O, Yau S, Yuen KT, et al. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960–2000 . Clin Oncol . 2003;15:329–336
  131. Roti E , degli Uberti EC , Bondanelli M , Braverman LE . Thyroid papillary microcarcinoma: a descriptive and metaanalysis study . Eur J Endocrinol . 2008;159:659–673
  132. Cappelli C, Castellano M, Braga M, Gandossi E, Pirola I, De Martino E, et al  Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience . J Surg Oncol . 2007;95:555–560
  133. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al  Microcarcinoma of the thyroid gland: the Gustave Roussy Institute experience . Cancer . 1998;83:553–559
  134. Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, et al  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients . J Clin Endocrinol Metab . 2006;91:2171–2178
  135. Chan BK , Desser TS , McDougall IR , Weigel RJ , Jeffrey RB . Common and uncommon sonographic features of papillary thyroid carcinoma . J Ultrasound Med . 2003;22:1083–1090
  136. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, et al  Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings . Head Neck . 2010;32:38–45
  137. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al  Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma . Ann Surg Oncol . 2009;16:240–245
  138. Lee TI, Yang HJ, Lin SY, Lee MT, Lin HD, Braverman LE, et al. The accuracy of fine-needle aspiration biopsy and frozen section in patients with thyroid cancer . Thyroid . 2002;12:619–626
  139. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma . J Clin Endocrinol Metab . 2004;89:5175–5180
  140. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, et al  Mutational analysis of BRAF in fine-needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules . Clin Cancer Res . 2004;10:2761–2765
  141. Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Di Coscio G, et al  A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates . Thyroid . 2009;19:837–842
  142. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, et al  BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies . Eur J Endocrinol . 2009;161:467–473
  143. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules . J Clin Endocrinol Metab . 2009;94:2092–2098
  144. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, et al  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer . J Clin Oncol . 2009;27:2977–2982
  145. Sala E , Mologni L , Truffa S , Gaetano C , Bollag GE , Gambacorti-Passerini C . BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells . Mol Cancer Res . 2008;6:751–759
  146. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins . Cancer Res . 2008;68:6145–6153
  147. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al  BRAF mutation predicts sensitivity to MEK inhibition . Nature . 2006;439:358–362
  148. Liu D , Liu Z , Jiang D , Dackiw AP , Xing M . Inhibitory effects of the MEK inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations . J Clin Endocrinol Metab . 2007;92:4686–4695
  149. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al  Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies . J Clin Oncol . 2005;23:5281–5293
  150. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer . J Clin Oncol . 2004;22:4456–4462
  151. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, et al  Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice . Mol Cancer Ther . 2007;6:1785–1792
  152. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al  Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis . Br J Cancer . 2006;95:581–586
  153. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al  Phase II trial of sorafenib in advanced thyroid cancer . J Clin Oncol . 2008;26:4714–4719
  154. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al  Phase II trial of sorafenib in metastatic thyroid cancer . J Clin Oncol . 2009;27:1675–1684
  155. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al  Motesanib diphosphate in progressive differentiated thyroid cancer . N Engl J Med . 2008;359:31–42
  156. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study . J Clin Oncol . 2008;26:4708–4713

PII: S1726-4901(10)70025-3

doi:10.1016/S1726-4901(10)70025-3

Journal of the Chinese Medical Association
Volume 73, Issue 3 , Pages 113-128, March 2010

Article Tools